Cargando…
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia
Most cancer cells have high need for nicotinamide adenine dinucleotide (NAD(+)) to sustain their survival. This led to the development of inhibitors of nicotinamide (NAM) phosphoribosyltransferase (NAMPT), the rate-limiting NAD(+) biosynthesis enzyme from NAM. Such inhibitors kill cancer cells in pr...
Autores principales: | ElMokh, Oussama, Matsumoto, Saki, Biniecka, Paulina, Bellotti, Axel, Schaeuble, Karin, Piacente, Francesco, Gallart-Ayala, Hector, Ivanisevic, Julijana, Stamenkovic, Ivan, Nencioni, Alessio, Nahimana, Aimable, Duchosal, Michel A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993809/ https://www.ncbi.nlm.nih.gov/pubmed/35396381 http://dx.doi.org/10.1038/s41419-022-04763-3 |
Ejemplares similares
-
Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia
por: Matsumoto, Saki, et al.
Publicado: (2023) -
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent
por: Cloux, Anne-Julie, et al.
Publicado: (2019) -
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies
por: Biniecka, Paulina, et al.
Publicado: (2023) -
Sex‐specific alterations in NAD+ metabolism in 3xTg Alzheimer’s disease mouse brain assessed by quantitative targeted LC‐MS
por: van der Velpen, Vera, et al.
Publicado: (2021) -
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery
por: Ghanem, Moustafa S., et al.
Publicado: (2022)